[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.194.190. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 546
Citations 0
Comment & Response
June 18, 2014

Withdrawal of Personal Genome Service

Author Affiliations
  • 1Health Council of the Netherlands, the Hague, the Netherlands
JAMA. 2014;311(23):2441. doi:10.1001/jama.2014.5570

To the Editor Reading the Viewpoint by Mr Downing and Dr Ross1 about the US Food and Drug Adminstration’s mandated withdrawal of 23andMe’s Personal Genome Service (PGS), I was confident the authors were working toward a conclusion stating the need to establish analytical as well as clinical validity. However, the authors concluded “When it becomes clear that the sequencing process used by the PGS is accurate, the use of this product could be allowed under the supervision of a physician.” This conclusion indicates analytical validity only.

×